Estrogen increases apolipoprotein (Apo) A-I secretion in Hep G2 cells by modulating transcription of the apo A-I gene promoter

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 12, 1999, Pages 2960-2965

  Lamon Fava, Stefania ^a   Ordovas, Jose M ^a   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

17 estradiol; Apolipoprotein A I; Estrogen receptor

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN C3; CALCIUM CHLORIDE; CALCIUM PHOSPHATE; ESTRADIOL; ESTROGEN;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; LIPOPROTEIN SYNTHESIS; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

EID: 0033398823     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.12.2960     Document Type: Article

References (41)

1. Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet. 1975;1:16-19.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707-714.
3. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO, for the MRFIT Research Group. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Am Heart J. 1986;112:825-836.
4. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB Jr. Plasma apolipoprotein A-I absence associated with marked reduction of high density lipoproteins and premature coronary heart disease. Arteriosclerosis. 1982; 2:16-26.
5. Karathanasis SK, Haddad I. DNA inversion within the apolipoprotein A-I/C-III/A-IV encoding gene cluster of certain patients with premature atherosclerosis. Proc Natl Acad Sci U S A. 1987;84:7198-7202.
6. Ordovas JM, Cassidy DK, Civeira F, Bisgaier CL, Schaefer EJ. Familial apolipoprotein A-I, C-III, and A-IV deficiency with marked high density lipoprotein deficiency and premature atherosclerosis due to a deletion of the apolipoprotein A-I, C-III. and A-IV gene complex. J Biol Chem. 1989;264:16339-16342.
7. Lamon-Fava S, Ordovas JM, Mandel G, Forte TM, Goodman RH, Schaefer EJ. Secretion of apolipoprotein A-I in lipoprotein particles following transfection of the human apolipoprotein A-I gene into 3T3 cells. J Biol Chem. 1987;262:8944-8947.
8. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med. 1991;20:47-63.
9. Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer HB Jr, Levy RI. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab. 1983;57:262-267.
10. Granfone A, Campos H, McNamara JR, Schaefer MM, Lamon-Fava S, Ordovas JM, Schaefer EJ. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism. 1992;41:1193-1198.
11. Applebaum-Bowden D, McLean P, Steinmetz A, Fontana D, Matthys C, Warnick GR, Cheung M, Albers JJ, Hazzard WR. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen admimstration in postmenopausal women. J Lipid Res. 1989;30:1895-1906.
12. Brinton EA. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotem A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol. 1996;16:431-440.
13. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res. 1994l35:2083-2093.
14. Archer TK, Tam S-P, Deeley RG. Kinetics of estrogen-dependent modulation of apolipoprotein A-I synthesis in human hepatoma cells. J Biol Chem. 1986;261:5067-5074.
15. Jin J-Y Kamanna VS, Kashyap ML. Estradiol stimulates apolipoprotein A-I- but not A-II-containing particle synthesis and secretion by stimulating mRNA transcription rate in Hep G2 cells. Arterioscler Thromb Vasc Biol. 1998;18:999-1006.
16. Beato M, Chavez S, Truss M. Transcriptional regulation by steroid hormones. Steroids. 1996;61:240-251.
17. Webb P Lopez GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol. 1995;9:443-456.
18. Binder R, Hwang S-PL, Ratnasabapathy R, Williams DL. Degradation of apolipoprotein II mRNA occurs via endonucleolytic cleavage at 5′-AAU-3′/5′-UAA-3′ elements in single-stranded loop domains of the 3′-noncoding region. J Biol Chem. 1989;264:16910-16918.
19. Vandenbrouck Y, Janvier B, Loriette C, Bereziat G, Mangeney-Andreani M. Thyroid hormone modulates apolipoprotein A-I gene expressron at the post-transcriptional level in HepG2 cells. Eur J Biochem. 1995;231:126-131.
20. Sastry KN, Seedorf U, Karathanasis SK. Different cis-acting DNA elements control expression of the human apolipoprotein A-I gene in different cell types. Mol Cell Biol. 1988;8:605-614.
21. Widom RL, Ladias JAA, Kouidou S, Karathanasis SK. Synergistic interaction between transcription factors control expression of the apolipoprotein A-I gene in liver cells. Mol Cell Biol. 1991;11:677-687.
22. Rottman JN, Widom RL, Nadal-Ginard B, Mahdavi V, Karathanasis SK. A retinoic acid-responsive element in the apolipoprotein A-I gene distinguishes between two different retinoic acid response pathways. Mol Cell Biol. 1991;11:3814-3820.
23. Ladias JAA, Karathanasis SK. Regulation of the apolipoprotein A-I gene by ARP-1, a novel member of the steroid receptor superfamily. Science. 1991;251:561-565.
24. Harnish DC, Malik S, Kilbourne E, Costa R, Karathanasis SK. Control of apolipoprotein A-I gene expression through synergistic interaction between hepatocyte nuclear factors 3 and 4. J Biol Chem. 1996;271: 13621-13628.
25. Ginsburg GS, Ozer J, Karathanasis SK. Intestinal apolipoprotein A-I gene transcription is regulated by multiple distinct DNA elements and is synergistically activated by the orphan nuclear receptor, hepatocyte nuclear factor 4. J Clin Invest. 1995;96:528-538.
26. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989.
27. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PWF. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res. 1994;35: 871-882.
28. Harnish DC, Evans MJ, Scicchitano MS, Bhat RA, Karathanasis SK. Estrogen regulation of the apolipoprotein A-I gene promoter through transcription cofactor sharing. J Biol Chem. 1998;273:9270-9278.
29. Kumar V, Green S, Stack G, Berry M, Jin J-R, Chambon P. Functional domains of the human estrogen receptor. Cell. 1987;51:941-951.
30. Kaufman RJ, Davies MV, Pathak VK, Hershey WB. The phosphorylation state of eucaryotic initiation factor 2 alters translational efficiency of specific mRNAs. Mol Cell Biol. 1989;9:946-958.
31. Lamon-Fava S, Sastry R, Ferrari S, Rajavashisth TB, Lusis AJ, Karathanasis SK. Evolutionary distinct mechanisms regulate apolipoprotein A-I gene expression: differences between avian and mammalian apo A-I gene transcription control regions. J Lipid Res. 1992;33: 831-842.
32. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High density lipoprotem cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
33. Slater EP, Redeuihl G, Theis K, Suske G, Beato M. The uteroglobulin promoter contains a noncanonical estrogen responsive element. Mol Endocrinol. 1990;4:604-610.
34. Liu Y, Teng CT. Estrogen response module of the mouse lactoferrin gene contains overlapping chicken ovalbumin upstream promoter transcription factor and estrogen receptor-binding elements. Mol Endocrinol. 1992;6: 355-364.
35. Berry M, Nunez A-M, Chambon P. Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci U S A. 1989;86:1218-1222.
36. Kato S, Tora L, Yamagushi J, Masushige S, Bellard M, Chambon P. A far upstream estrogen response element of the ovalbumin gene contains several half-palindromic 5′-TGACC-3′ motifs acting synergistically. Cell. 1992;68:731-742.
37. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996;93:5925-5930.
38. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su J-L, Kliewer SA, Lehmann JM, Willson TM. Cloning and characterization of human estrogen receptor β isoforms. Biochem Biophys Res Commun. 1998;247:75-78.
39. Kuiper GGJM, Gustafsson J-A. The novel estrogen receptor β subtype: potential role in the cell- and promoter-specific actions of estrogens and antiestrogens. FEBS Lett. 1997;410:87-90.
40. Maaroufi Y, Hardouze AB, Leclercq G. Decrease of hormone binding capacity of estrogen receptor by calcium. J Recept Signal Transduct Res. 1997;17:833-853.
41. Goyache FM, Gutierrez M, Hidalgo A, Cantabrana B. Non-genomic effects of catecholestrogens in the in vitro rat uterine contraction. Gen Pharmacol. 1995;26:219-223.